



Acinetobacter baumannii (CRAB) – Pneumonia

Procedure Summary

- Immunocompetent BALB/cByJ mice, eight weeks old females
- *Acinetobacter baumannii*
 - Wild type ATCC 17978
 - Carbapenem Resistant (CRAB) clinical strains
- Neutropenic status induced by 2 cyclophosphamide intraperitoneal (IP) administrations at D-4; 150mg/kg and D-1; 100mg/kg
- Intranasal challenge (50 μ L)
- Reference compounds: Colistin (20mg/kg every 8h, sc), Rifampin (20 mg/kg every 6h, IP), meropenem (100 mg/kg every 2h, IP) or combined therapies, 2h post-infection.

Experimental readouts

- CFU determination of *A. baumannii* strain in lungs and spleen
- Survival rate
- Weight loss
- Clinical score

Optional Services

- Microbiological analysis
- Cytokine and chemokine analysis
- Pharmacokinetics

Animal Welfare

- Each experimental protocol is approved by the local ethics committee for animal experimentation of Grand Campus Dijon (Burgundy, France) and performed in accordance to the current recommendations of the European Institute of Health EU Directive 86/609


Facilities

- These assays are performed at our BSL2 laboratory / zootechnical center in Dijon, France


Reference

- Internal Data

Evaluation of the efficacy of different antibiotics on the residual bacterial load in the neutropenic mouse model of *Acinetobacter baumannii* ATCC 17978 lung infection.



Evaluation of the efficacy of different antibiotics on the residual bacterial load in the neutropenic mouse model of carbapenem-resistant *Acinetobacter baumannii* lung infection.



Our scientific team will readily accommodate client-specific alterations and will provide expert advice and guidance for your efficacy studies

For more information please contact: info@vivexia.fr